Blog
Published May 23, 2024
Executive Summary
The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market attractiveness. A few key developments announced or already implemented include:
The shift of the much-debated Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) to…
Read Now
Blog
Published May 17, 2024
Executive Summary
The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024.
Some key features of the reform plan include:
The creation of premiums for incentivizing the early introduction of new innovative therapies in Japan
The establishment of post-listing price adjustment scheme by average foreign price for specific imported drugs at the time of price revision
The simplification of the price maintenance premium (PMP) system so…
Read Now
Webinars
Available On Demand
A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively discussion on the benefits of rapid access to cumulative, compounded learnings generated from in-depth analysis of global HTA recommendations, with presenters Mary Fletcher-Louis, Managing Director…
Watch Now
Blog
Published April 22, 2024
Executive Summary
The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system.
The 2024 PLFSS emphasizes:
Drug access and cost containment, with a higher payback trigger aimed at reducing the government’s payback collections
Temporary reimbursement to ensure continuous treatment of patients with medicines benefitting from the early…
Read Now
Webinars
Available On Demand
How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL?
As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for manufacturers aiming to achieve successful access and pricing outcomes.
In this webinar, a panel of Trinity Life Sciences’ Value, Access and Pricing experts will discuss the role of the new value-based assessment framework in NRDL payer decision-making and dive…
Watch Now
Blog
Published March 20, 2024
Executive Summary
The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the appointment of a new acting chairman, highlighting the need for a stable and collaborative leadership within AIFA.
Although AIFA’s overhaul has been implemented following a year-long delay due to bureaucratic complexities and is currently facing uncertainties, it will be…
Read Now
Webinars
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the impacts for pharma manufacturers.
Register for this webinar for a deeper dive into a few trends in the white paper. Join experts from our Evidence,…
Watch Now
Blog
Published February 26, 2024
Executive Summary
Multiple cost-containment reforms, such as the introduction of a 20% rebate on brand-brand combinations and a temporary increase in the mandatory rebate on drugs to 12%, were implemented under Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz) in 2023. The evaluation report of these strategies showed that the actual savings for the year fell short of the proposed target (25% deficit, €1.4 Bn vs. target of €1.9 Bn) for all such reforms except 30% higher savings…
Read Now
Blog
Published December 7, 2023
Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both academics and the life sciences industry, including manufacturers, regulatory leaders and health economists, to consider the latest challenges and opportunities being addressed by health economics and outcomes research. Topics included Joint Clinical Assessments (JCAs), access to innovative therapies, environmental…
Read Now
Blog
Published November 7, 2023
In August 2023, the Colombian government published a new pricing policy outlining that the list price of new medicines in Colombia will be established based on their therapeutic value category, resulting from an assessment conducted by the Instituto de Evaluation Tecnológica en Salud (IETS). The outcomes of the therapeutic assessment are then reported to the National Commission for Prices of Medicines and Medical Devices (CNPMDM), which is responsible for setting the list price of the new drugs. Up until now,…
Read Now
